|
News For TEVA;MYL;AZN From The Last 14 Days Check below for free stories on TEVA;MYL;AZN the last two weeks. |
|
|
| May 22, 2013 |
| 16:23 EDT |  | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
 Subscribe for More Information |
|
| 11:53 EDT |  | MYL | High option volume stocks: UAN MYL ALNY SKS XIDE
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| May 21, 2013 |
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 11:27 EDT | | MYL, TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 14:48 EDT |  | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 10:36 EDT |  | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
| |
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
|
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| 07:24 EDT | | AZN | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 16:53 EDT | | AZN | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link |
|
| 15:55 EDT | | AZN | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information |
| |
|
|
|
|
